NYSEAMERICAN:NAVB - Navidea Biopharmaceuticals Stock Price, Forecast & News

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) posted its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.17). The biopharmaceutical company earned $0.24 million during the quarter. View Navidea Biopharmaceuticals' Earnings History.

Navidea Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Navidea Biopharmaceuticals.

2 Wall Street analysts have issued 1 year price targets for Navidea Biopharmaceuticals' stock. Their forecasts range from $2.00 to $3.00. On average, they expect Navidea Biopharmaceuticals' stock price to reach $2.50 in the next year. This suggests a possible upside of 123.2% from the stock's current price. View Analyst Price Targets for Navidea Biopharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Navidea Biopharmaceuticals.

News headlines about NAVB stock have been trending negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Navidea Biopharmaceuticals earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Navidea Biopharmaceuticals.

Navidea Biopharmaceuticals saw a drop in short interest in January. As of January 31st, there was short interest totalling 664,900 shares, a drop of 7.0% from the January 15th total of 715,300 shares. Based on an average daily trading volume, of 608,700 shares, the short-interest ratio is currently 1.1 days. Approximately 6.0% of the shares of the company are short sold. View Navidea Biopharmaceuticals' Current Options Chain.

Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include NovaBay Pharmaceuticals (NBY), Inovio Pharmaceuticals (INO), Opko Health (OPK), Novavax (NVAX), Rexahn Pharmaceuticals (REXN), AcelRx Pharmaceuticals (ACRX), Agenus (AGEN), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL) and Gilead Sciences (GILD).

Navidea Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Allred Capital Management LLC (0.13%). Company insiders that own Navidea Biopharmaceuticals stock include Claudine Bruck, Jed Latkin, John K Jr Scott and Sarah Kathryn Rouan. View Institutional Ownership Trends for Navidea Biopharmaceuticals.

NAVB stock was purchased by a variety of institutional investors in the last quarter, including Allred Capital Management LLC. Company insiders that have bought Navidea Biopharmaceuticals stock in the last two years include Claudine Bruck, Jed Latkin, John K Jr Scott and Sarah Kathryn Rouan. View Insider Buying and Selling for Navidea Biopharmaceuticals.

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NAVB stock can currently be purchased for approximately $1.12.

Navidea Biopharmaceuticals has a market capitalization of $20.25 million. Navidea Biopharmaceuticals employs 14 workers across the globe.View Additional Information About Navidea Biopharmaceuticals.

The official website for Navidea Biopharmaceuticals is http://www.navidea.com/.

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.